celecoxib has been researched along with Alzheimer Disease in 41 studies
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the effectiveness and adverse effects of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) for the primary or secondary prevention of dementia." | 9.05 | Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia. ( Devane, D; Jordan, F; Kelly, JP; McGuinness, B; Murphy, K; Passmore, P; Quinn, TJ; Tudur Smith, C, 2020) |
| "To evaluate the efficacy and safety of naproxen and celecoxib for the primary prevention of Alzheimer disease (AD)." | 5.12 | Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. ( Breitner, JC; Green, RC; Lyketsos, CG; Martin, BK; Meinert, C; Piantadosi, S; Sabbagh, M, 2007) |
| "To evaluate the effectiveness and adverse effects of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) for the primary or secondary prevention of dementia." | 5.05 | Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia. ( Devane, D; Jordan, F; Kelly, JP; McGuinness, B; Murphy, K; Passmore, P; Quinn, TJ; Tudur Smith, C, 2020) |
| "Naproxen was detected in cerebrospinal fluid at concentrations ~100 times lower than in plasma, but produced negligible change in immune markers." | 2.90 | No apparent effect of naproxen on CSF markers of innate immune activation. ( Breitner, JCS; Labonté, A; Meyer, PF; Poirier, J; Rosa-Neto, P, 2019) |
| "We simulated data based on the Alzheimer's Disease Anti-Inflammatory Prevention Trial, and a range of sample sizes, biomarker positive predictive values, and treatment effects." | 2.79 | Simulating effects of biomarker enrichment on Alzheimer's disease prevention trials: conceptual framework and example. ( Bartlett, AL; Forrester, SN; Leoutsakos, JM; Lyketsos, CG, 2014) |
| "We used data from the Alzheimer's Disease Anti-Inflammatory Prevention Trial to compare performance of a four-test Telephone Assessment Battery (TAB) that included the Telephone Interview for Cognitive Status (TICS) to that of a traditional in-person Cognitive Assessment Battery." | 2.78 | Screening by telephone in the Alzheimer's disease anti-inflammatory prevention trial. ( Brandt, J; Breitner, JC; Luis, CA; Martin, B; Reckess, GZ; Zandi, P, 2013) |
| "Celecoxib 200 mg bid did not slow the progression of AD in this study, and the occurrence of adverse events was as expected for an elderly population with a complex chronic medical condition." | 2.73 | Long-term efficacy and safety of celecoxib in Alzheimer's disease. ( Niculescu, L; Robbins, J; Soininen, H; West, C, 2007) |
| "Among the most widely prescribed drugs worldwide, non-steroidal anti-inflammatory drugs (NSAIDs) are effective for relieving pain, but they are also associated with a high incidence of gastrointestinal (GI) adverse events." | 2.41 | Do selective cyclo-oxygenase inhibitors eliminate the adverse events associated with nonsteroidal anti-inflammatory drug therapy? ( Devière, J, 2002) |
| " RATIONALE FOR THE USE OF SELECTIVE COX-2 INHIBITORS: The rationale for the prescription of selective COX-2 inhibitors as neuroprotective drugs in AD lies on: Epidemiological data having shown a reduced risk of developing AD in patients treated with anti-inflammatory doses of classical NSAIDs (inhibition of COX-1 and COX-2) but not with antithrombotic doses of aspirin (selective inhibition of COX-1), Cellular experiments, Demonstration of a better gastro-intestinal (GI) safety profile with selective COX-2 inhibitors than with classical NSAIDs in short-term studies, allowing a possible long-term use in AD." | 2.41 | [Non-steroidal anti-inflammatory drugs with selectivity for cyclooxygenase-2 in Alzheimer's disease. Rationale and perspectives]. ( Blain, A; Blain, H; Jeandel, C; Jouzeau, JY; Netter, P; Terlain, B; Touchon, J; Tréchot, P, 2000) |
| " Moreover, some epidemiologic and pilot clinical studies have proven that long-term administration of anti-inflammatory drugs have a protective effect on the onset of AD." | 2.41 | Alzheimer's disease, inflammation and non-steroidal anti-inflammatory drugs. ( Ferencik, M; Novak, M; Rovensky, J; Rybar, I, 2001) |
| "Celecoxib/STZ treatments produced a significant loss of learning and memory." | 1.35 | Modulation of celecoxib- and streptozotocin-induced experimental dementia of Alzheimer's disease by pitavastatin and donepezil. ( Sharma, B; Singh, M; Singh, N, 2008) |
| " Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin for arthritis decreases the risk of developing Alzheimer's disease (AD) by unknown mechanisms." | 1.31 | Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-beta aggregation. ( Nadackal, TG; Thomas, K; Thomas, T, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.44) | 18.2507 |
| 2000's | 22 (53.66) | 29.6817 |
| 2010's | 15 (36.59) | 24.3611 |
| 2020's | 3 (7.32) | 2.80 |
| Authors | Studies |
|---|---|
| AlFadly, ED | 1 |
| Elzahhar, PA | 1 |
| Tramarin, A | 1 |
| Elkazaz, S | 1 |
| Shaltout, H | 1 |
| Abu-Serie, MM | 1 |
| Janockova, J | 1 |
| Soukup, O | 1 |
| Ghareeb, DA | 1 |
| El-Yazbi, AF | 1 |
| Rafeh, RW | 1 |
| Bakkar, NZ | 1 |
| Kobeissy, F | 1 |
| Iriepa, I | 1 |
| Moraleda, I | 1 |
| Saudi, MNS | 1 |
| Bartolini, M | 1 |
| Belal, ASF | 1 |
| Sagar, SR | 1 |
| Singh, DP | 1 |
| Das, RD | 1 |
| Panchal, NB | 1 |
| Sudarsanam, V | 1 |
| Nivsarkar, M | 1 |
| Vasu, KK | 1 |
| Hu, H | 1 |
| Wang, J | 1 |
| Ren, J | 1 |
| Li, X | 1 |
| Zhang, B | 1 |
| Lv, Z | 1 |
| Dai, F | 1 |
| Jordan, F | 1 |
| Quinn, TJ | 1 |
| McGuinness, B | 1 |
| Passmore, P | 1 |
| Kelly, JP | 1 |
| Tudur Smith, C | 1 |
| Murphy, K | 1 |
| Devane, D | 1 |
| Guo, JW | 1 |
| Guan, PP | 1 |
| Ding, WY | 1 |
| Wang, SL | 1 |
| Huang, XS | 1 |
| Wang, ZY | 1 |
| Wang, P | 1 |
| Singh, R | 1 |
| Thota, S | 1 |
| Bansal, R | 1 |
| Meyer, PF | 1 |
| Labonté, A | 1 |
| Rosa-Neto, P | 1 |
| Poirier, J | 1 |
| Breitner, JCS | 1 |
| Reckess, GZ | 1 |
| Brandt, J | 3 |
| Luis, CA | 1 |
| Zandi, P | 1 |
| Martin, B | 1 |
| Breitner, JC | 8 |
| Hori, K | 1 |
| Konishi, K | 1 |
| Akita, R | 1 |
| Tanaka, H | 1 |
| Hachisu, M | 1 |
| Leoutsakos, JM | 2 |
| Bartlett, AL | 1 |
| Forrester, SN | 1 |
| Lyketsos, CG | 4 |
| Zhu, L | 1 |
| Ploessl, K | 1 |
| Kung, HF | 1 |
| DiBattista, AM | 1 |
| Dumanis, SB | 1 |
| Newman, J | 1 |
| Rebeck, GW | 1 |
| Meinert, CL | 2 |
| McCaffrey, LD | 1 |
| Bregman, N | 1 |
| Karni, A | 1 |
| Korczyn, AD | 1 |
| Choi, JK | 1 |
| Jenkins, BG | 1 |
| Carreras, I | 1 |
| Kaymakcalan, S | 1 |
| Cormier, K | 1 |
| Kowall, NW | 1 |
| Dedeoglu, A | 1 |
| Montine, TJ | 2 |
| Sonnen, JA | 1 |
| Milne, G | 1 |
| Baker, LD | 2 |
| Muthen, BO | 1 |
| Ashe, KH | 1 |
| Craft, S | 2 |
| Evans, DE | 1 |
| Green, RC | 2 |
| Ismail, MS | 1 |
| Martin, BK | 3 |
| Mullan, MJ | 1 |
| Sabbagh, M | 2 |
| Tariot, PN | 1 |
| Aisen, PS | 1 |
| Helmuth, L | 1 |
| Devière, J | 1 |
| Burdan, F | 1 |
| Korobowicz, A | 1 |
| Yokota, O | 1 |
| Terada, S | 1 |
| Ishihara, T | 1 |
| Nakashima, H | 1 |
| Kugo, A | 1 |
| Ujike, H | 1 |
| Tsuchiya, K | 1 |
| Ikeda, K | 1 |
| Saito, Y | 1 |
| Murayama, S | 1 |
| Ishizu, H | 1 |
| Kuroda, S | 1 |
| Couzin, J | 2 |
| Kukar, T | 1 |
| Murphy, MP | 1 |
| Eriksen, JL | 1 |
| Sagi, SA | 1 |
| Weggen, S | 1 |
| Smith, TE | 1 |
| Ladd, T | 1 |
| Khan, MA | 1 |
| Kache, R | 1 |
| Beard, J | 1 |
| Dodson, M | 1 |
| Merit, S | 1 |
| Ozols, VV | 1 |
| Anastasiadis, PZ | 1 |
| Das, P | 1 |
| Fauq, A | 1 |
| Koo, EH | 1 |
| Golde, TE | 1 |
| Sahagan, BG | 1 |
| Stephenson, DT | 1 |
| Hounslow, N | 1 |
| Liston, DR | 1 |
| Manning, PT | 1 |
| Melnikova, T | 1 |
| Savonenko, A | 1 |
| Wang, Q | 1 |
| Liang, X | 1 |
| Hand, T | 1 |
| Wu, L | 1 |
| Kaufmann, WE | 1 |
| Vehmas, A | 1 |
| Andreasson, KI | 1 |
| Soininen, H | 1 |
| West, C | 1 |
| Robbins, J | 1 |
| Niculescu, L | 1 |
| Meinert, C | 1 |
| Piantadosi, S | 2 |
| Sharma, B | 1 |
| Singh, N | 1 |
| Singh, M | 1 |
| Szekely, C | 1 |
| Evans, D | 1 |
| Green, R | 1 |
| Mullan, M | 1 |
| Pascucci, RA | 1 |
| Blain, H | 1 |
| Jouzeau, JY | 1 |
| Blain, A | 1 |
| Terlain, B | 1 |
| Tréchot, P | 1 |
| Touchon, J | 1 |
| Netter, P | 1 |
| Jeandel, C | 1 |
| Ferencik, M | 1 |
| Novak, M | 1 |
| Rovensky, J | 1 |
| Rybar, I | 1 |
| Thomas, T | 1 |
| Nadackal, TG | 1 |
| Thomas, K | 1 |
| Jantzen, PT | 1 |
| Connor, KE | 1 |
| DiCarlo, G | 1 |
| Wenk, GL | 1 |
| Wallace, JL | 1 |
| Rojiani, AM | 1 |
| Coppola, D | 1 |
| Morgan, D | 1 |
| Gordon, MN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)[NCT00007189] | Phase 3 | 2,625 participants | Interventional | 2001-01-31 | Completed | ||
| Alzheimer's Disease Anti-Inflammatory Prevention Trial Follow-Up Study[NCT01417130] | 1,650 participants (Anticipated) | Observational | 2009-08-31 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for celecoxib and Alzheimer Disease
| Article | Year |
|---|---|
Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Age | 2020 |
Anti-inflammatory agents in Alzheimer's disease.
Topics: Alzheimer Disease; Anti-Inflammatory Agents; Celecoxib; Humans; Hydroxychloroquine; Prednisone; Pyra | 2002 |
Do selective cyclo-oxygenase inhibitors eliminate the adverse events associated with nonsteroidal anti-inflammatory drug therapy?
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Hu | 2002 |
[Coxibs: highly selective cyclooxygenase-2 inhibitors. Part I. Clinical efficacy].
Topics: Alzheimer Disease; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibito | 2003 |
NSAIDs and Alzheimer's disease: how far to generalise from trials?
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Humans; Naproxen; Pyrazoles; | 2003 |
[Non-steroidal anti-inflammatory drugs with selectivity for cyclooxygenase-2 in Alzheimer's disease. Rationale and perspectives].
Topics: Adult; Age Factors; Aged; Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain | 2000 |
Alzheimer's disease, inflammation and non-steroidal anti-inflammatory drugs.
Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain; Celecoxib; Cyclooxygenas | 2001 |
12 trials available for celecoxib and Alzheimer Disease
| Article | Year |
|---|---|
No apparent effect of naproxen on CSF markers of innate immune activation.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Celecoxib; Cytokines; Female | 2019 |
Results of a follow-up study to the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT).
Topics: Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents; Celecoxib; Cognit | 2013 |
Screening by telephone in the Alzheimer's disease anti-inflammatory prevention trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Celecoxib; Cognition Disorders; Female; Geriatric Assess | 2013 |
Simulating effects of biomarker enrichment on Alzheimer's disease prevention trials: conceptual framework and example.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents; Biomarkers; Celecoxib; Compute | 2014 |
Follow-up evaluation of cognitive function in the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial and its Follow-up Study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents; Celecoxib; Cognition; Female; | 2015 |
Follow-up evaluation of cognitive function in the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial and its Follow-up Study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents; Celecoxib; Cognition; Female; | 2015 |
Follow-up evaluation of cognitive function in the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial and its Follow-up Study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents; Celecoxib; Cognition; Female; | 2015 |
Follow-up evaluation of cognitive function in the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial and its Follow-up Study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents; Celecoxib; Cognition; Female; | 2015 |
Alzheimer's Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Brain; Celecoxi | 2009 |
Elevated ratio of urinary metabolites of thromboxane and prostacyclin is associated with adverse cardiovascular events in ADAPT.
Topics: 6-Ketoprostaglandin F1 alpha; Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, | 2010 |
Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cogn | 2012 |
Extended results of the Alzheimer's disease anti-inflammatory prevention trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Anti-Inflammatory Agents, Non-Ste | 2011 |
Long-term efficacy and safety of celecoxib in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cognition Disorders; De | 2007 |
Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial.
Topics: Adult; Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Brain; Celecoxib; Cyclooxyg | 2007 |
Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial.
Topics: Adult; Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Brain; Celecoxib; Cyclooxyg | 2007 |
Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial.
Topics: Adult; Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Brain; Celecoxib; Cyclooxyg | 2007 |
Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial.
Topics: Adult; Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Brain; Celecoxib; Cyclooxyg | 2007 |
Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cogn | 2008 |
Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cogn | 2008 |
Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cogn | 2008 |
Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cogn | 2008 |
22 other studies available for celecoxib and Alzheimer Disease
| Article | Year |
|---|---|
Tackling neuroinflammation and cholinergic deficit in Alzheimer's disease: Multi-target inhibitors of cholinesterases, cyclooxygenase-2 and 15-lipoxygenase.
Topics: Acetylcholine; Alzheimer Disease; Animals; Cell Line; Cholinesterase Inhibitors; Cyclooxygenase 2 In | 2019 |
Investigations on substituted (2-aminothiazol-5-yl)(imidazo[1,2-a]pyridin-3-yl)methanones for the treatment of Alzheimer's disease.
Topics: Aluminum Chloride; Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Dose-Respons | 2021 |
Hydrophilic polymer driven crystallization self-assembly: an inflammatory multi-drug combination nanosystem against Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Celeco | 2021 |
Erythrocyte membrane-encapsulated celecoxib improves the cognitive decline of Alzheimer's disease by concurrently inducing neurogenesis and reducing apoptosis in APP/PS1 transgenic mice.
Topics: 14-3-3 Proteins; Adaptor Proteins, Signal Transducing; Alzheimer Disease; Amyloid beta-Peptides; Ani | 2017 |
Studies on 16,17-Pyrazoline Substituted Heterosteroids as Anti-Alzheimer and Anti-Parkinsonian Agents Using LPS Induced Neuroinflammation Models of Mice and Rats.
Topics: Alzheimer Disease; Animals; Antiparkinson Agents; Brain; Celecoxib; Dexamethasone; Drug Evaluation, | 2018 |
Fluvoxamine and celecoxib may have caused adverse events in an elderly patient.
Topics: Aged, 80 and over; Alzheimer Disease; Amnesia; Anti-Inflammatory Agents, Non-Steroidal; Antidepressi | 2013 |
Chemistry. Expanding the scope of fluorine tags for PET imaging.
Topics: Alzheimer Disease; Aniline Compounds; Celecoxib; Ethylene Glycols; Fluorescent Dyes; Fluorine Radioi | 2013 |
Identification and modification of amyloid-independent phenotypes of APOE4 mice.
Topics: Age Factors; Alzheimer Disease; Amyloid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apolipopr | 2016 |
Anti-inflammatory drugs fall short in Alzheimer's disease.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cognition; Humans; Naproxen; | 2008 |
Can treatment with nonsteroidal anti-inflammatory drugs protect from dementia?
Topics: Adult; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Humans; Naproxen; Pyra | 2009 |
Anti-inflammatory treatment in AD mice protects against neuronal pathology.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroi | 2010 |
NSAIDS for prevention? Protecting the brain while killing pain?
Topics: Alzheimer Disease; Amyloid beta-Peptides; Anti-Inflammatory Agents, Non-Steroidal; Brain; Celecoxib; | 2002 |
Neuronal expression of cyclooxygenase-2, a pro-inflammatory protein, in the hippocampus of patients with schizophrenia.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Autopsy; Celecoxib; Cyclooxygenase 2; Cyclooxygenase | 2004 |
Clinical trials. Nail-biting time for trials of COX-2 drugs.
Topics: Alzheimer Disease; Anticarcinogenic Agents; Cardiovascular Diseases; Celecoxib; Controlled Clinical | 2004 |
Clinical trials. Halt of Celebrex study threatens drug's future, other trials.
Topics: Alzheimer Disease; Celecoxib; Clinical Trials as Topic; Colonic Polyps; Cyclooxygenase Inhibitors; D | 2004 |
Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Anti-Inflammatory Ag | 2005 |
Killing pain, not neurons.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Celecoxib; Cyclooxygenase 2; Dose-Response Relati | 2005 |
Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Behavior, | 2006 |
Modulation of celecoxib- and streptozotocin-induced experimental dementia of Alzheimer's disease by pitavastatin and donepezil.
Topics: Acetylcholinesterase; Administration, Oral; Alzheimer Disease; Animals; Brain; Celecoxib; Disease Mo | 2008 |
COX-2-specific inhibition: implications for clinical practice.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Blood Platelets; Celecoxib; Colorectal N | 1999 |
Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-beta aggregation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxi | 2001 |
Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Anim | 2002 |